# Ferritin and transferrin predict common carotid intima-media thickness in females: a machine-learning informed individual participant data meta-analysis

Anand Ruban Agarvas[1,2], Richard Sparla[1,2], Janice L Atkins[3], Claudia Altamura[4], Todd Anderson[5], Ebru Asicioglu[6], Judit Bassols[7], Abel López-Bermejo[7], H M Dvořáková[8], José Manuel Fernández-Real[9,10], Christoph Hochmayr[11], Michael Knoflach[12,13], Jovana Kusic Milicevic[14], Silvia Lai[15], José María Moreno-Navarrete[7], Dariusz Pawlak[16], Krystyna Pawlak[17], Petr Syrovatka[18], Dorota Formanowicz[19], Pavel Kraml[20], Jose M Valdivielso[21], Luca Valenti[22,23], and Martina U. Muckenthaler[1,2,24,25,26,□]

2025-04-30

[1] Heidelberg University, Heidelberg, Germany.

[2] Center For Translational Biomedical Iron Research, Department of Pediatric Hematology, Oncology Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.

[3] Department of Clinical & Biomedical Sciences, Faculty of Health & Life Sciences, University of Exeter, United Kingdom.

[4] Unit of Headache and Neurosonology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.

[5] Department of Cardiac Sciences and Libin Cardiovascular Institute of Alberta (TJA), Cumming School of Medicine, University of Calgary, Alberta, Canada.

[6] Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey.

[7] Institut d'Investigació Biomèdica de Girona (IdIBGi), Hospital Trueta & Universitat de Girona, Girona, Spain.

[8] Department of Neonatology, University Hospital Prague-Motol, Prague, Czech Republic.

[9] Institut d'Investigació Biomèdica de Girona (IdIBGi), Hospital Trueta & Department of Medical Sciences, School of Medicine, Universitat de Girona, Girona, Spain.

[10] CIBERobn Fisiopatologia de la Obesidad y Nutrición, Madrid, Spain.

[11] Department of Pediatrics II (Neonatology), Medical University of Innsbruck, Innsbruck, Austria.

[12] Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

[13] VASCage, Centre on Clincial Stroke Research, Innsbruck, Austria.

[14] Department of Nephrology, Clinical Hospital Centre Zemun, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
[15] Department of Translational and Precision Medicine, Nephrology Unit, Sapienza University of Rome, Rome, Italy.
[16] Department of Pharmacodynamics, Medical University of Bialystok, Poland.
[17] Department of Monitored Pharmacotherapy, Medical University of Bialystok, Poland.
[18] Cardiocentre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
[19] Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poznan, Poland.
[20] Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic.
[21] Vascular and Renal Translational Research Group, IRBLleida, Lleida, Spain.
[22] Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy.
[23] Precision Medicine, SS Centro Risorse Biologiche, Fondazione IRCCS Ca' Granda Policlinico, Pad Marangoni via F Sforza 35, 20122, Milano, Italy.
[24] Molecular Medicine Partnership Unit, Heidelberg, Germany.
[25] Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL).
[26] German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Germany.

Correspondence: Martina U. Muckenthaler <Martina.Muckenthaler@med.uni-heidelberg.de>

# 1. Abstract


Background

Iron overload, associated with the appearance of non-transferrin-bound iron, promotes atherosclerosis in mice and causes vascular dysfunction in humans with Hemochromatosis and transfusion-dependent hemolytic anemias. However, data are controversial on whether systemic iron availability within physiological limits (as indicated by circulating iron biomarkers) affects the pathogenesis of atherosclerosis. To address this question systematically, we performed an individual participant data (IPD) meta-analysis and studied the association between the serum iron biomarkers [ferritin, transferrin, iron, and transferrin saturation (TSAT)] with carotid intima-media thickness (CC-IMT) and specifically, if there are sex-specific differences.

Methods

We pooled the IPD and analysed the data on adults (age≥18y) by orthogonal approaches: machine learning (ML) and a single-stage meta-analysis. For ML, we tuned a gradient-boosted tree regression model (XGBoost) and subsequently, we interpreted the features using variable importance. For the single-stage metaanalysis, we examined the association between iron biomarkers and CC-IMT using spline-based linear mixed models, accounting for sex interactions and study-specific effects. To confirm robustness, we repeated analyses on imputed data using multivariable regression adjusted for key covariates identified through machine learning. Further, subgroup analysis were performed in the children and adolescents (age<18y). In addition, we used UK Biobank data to examine associations between the hemochromatosis (HFE) genotypes (C282Y/H63D) and mean CC-IMT in ~42,500 participants with carotid ultrasound data, using sex-stratified linear regression (adjusted for age, assessment centre, and genetic principal components).

Results

We included IPD from 21 studies (N=10,807). The application of the ML model showed moderate predictive performance and identified iron biomarkers (transferrin, ferritin, TSAT, and iron) as key features for IMT prediction. In the analysis of unimputed data, higher ferritin levels were positively associated with CC-IMT, particularly in females with ferritin >233 ng/mL. Transferrin alone was not significant, but negative associations emerged at certain transferrin ranges among females. Multivariable analyses on the imputed data confirmed these sex-specific effects: ferritin showed a significant positive association, and transferrin showed negative associations at specific ranges, both only among females. No significant associations were found between CC-IMT in those with HFE genotypes in either sex in the UK Biobank.

Conclusion

Our data show that iron biomarkers - ferritin and transferrin are non-linearly associated with CC-IMT specifically in females. The dual role of ferritin and transferrin in iron metabolism and inflammation suggests that these processes could be interconnected in their effects on vascular health.

Other: No financial support was received for this meta-analysis. The protocol for this study is registered in the PROSPERO database (CRD42020155429; https://www.crd.york.ac.uk/).

## 2. Introduction

Iron is a vital nutrient involved in numerous cellular functions; however, iron accumulation can be pathological. We have previously shown that excess iron accelerates the pathogenesis of atherosclerosis[1]. Excess iron initiates redox reactions (via Fenton chemistry) that lead to oxidative damage of membrane lipids, proteins, and DNA. In addition, iron can also lead to endothelial injury, immune cell polarization, ferroptosis, and plaque destabilization, thereby, contributing to vascular dysfunction and atherosclerosis[1–3].

In the blood, iron biomarkers reflective of the systemic iron status [e.g., serum iron, ferritin, transferrin, transferrin saturation (TSAT), total iron binding capacity (TIBC) and hepcidin] can be quantified. Whether these iron biomarkers within physiological limits are associated with the pathogenesis of atherosclerosis is of clinical relevance but available data are conflicting. Our recent analysis in two cohorts found a positive association between ferritin and peripheral arterial disease preferentially in females, suggesting sex-specific effects[4]. In this current study, we investigated whether iron markers correlate with subclinical arteriopathy as indicated by sonographically assessed common carotid intima-media thickness (CC-IMT). Clinically, elevated CC-IMT is an independent predictor of a wide range of cardiovascular events[5,6].

The conclusions of previous, smaller studies that have evaluated the relationship between iron biomarkers and CC-IMT are inconsistent. Therefore, we conducted an individual participant data (IPD) meta-analysis to systematically investigate this clinically relevant question. The advantages of an IPD meta-analysis cannot be overstated: the collection and analysis of raw data from multiple studies provides a large participant-pool and thus a greater statistical power to detect of smaller effect sizes[7]. Working with raw data allows for standardized and flexible analyses, leading to more precise and reliable estimates.

We included a novel approach to the meta-analysis by using two orthogonal approaches for the meta-analysis: machine learning (ML) and regression, since both

offer unique advantages and drawbacks. ML excels at handling complex datasets, identifying nonlinear relationships, and making predictions without requiring strong assumptions about the data. However, one of the criticisms of ML is that it lacks interpretability. On the other hand, regression analysis provides interpretability, and enables testing of relationship between variables under specific assumptions. However, it may struggle with high-dimensional data and complex nonlinear patterns, as is the case with clinical data. Therefore, we used a combination of the approaches to leverage their strengths and to obtain a clear understanding of the relationships.

# 3. Methods

The protocol for the study is published in the PROSPERO database (CRD42020155429; https://www.crd.york.ac.uk/; Supplementary File 1). We report the study according to Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data (PRISMA-IPD; See Supplementary File 2 for checklist[8]). We used R version 4.3.1[9] for the data analysis and visualization (For the specific packages used, see Supplementary Table 1).

## 3.1 Literature search

We searched NLM Medline using the following string: (iron OR ferritin OR transferrin OR hepcidin) AND (atherosclerosis OR intima-media thickness). We applied filters for human studies published in English between 1st Oct 1999 and 20th Oct 2019 (last updated on 24th Aug 2023). We used a three-step process for the study selection. In step 1, we screened the titles of the published studies and excluded records when the titles were specified as reviews or were performed on preclinical models. In step 2, we screened the abstract for human studies with one of the following keywords: iron, ferritin, transferrin, hepcidin, atherosclerosis or intima-media thickness. In step 3, we screened the full text and if studies contained data on iron biomarkers [iron, ferritin, transferrin, hepcidin, or transferrin saturation (TSAT)] and CC-IMT, they were included in the IPD. Screening of the retrieved records was done independently by two investigators (ARA, RS).

## 3.2 Data collection

We contacted the investigators (first or corresponding authors) of eligible studies with the study protocol and requested formal consent for participation (for a scheme of data request, see Supplementary Figure 1). Through subsequent contact, we asked the investigators for anonymized data on the following variables: age, gender, CC-IMT, serum iron indices (iron, ferritin, transferrin, TSAT, hepcidin), ethnic profile, and presence of comorbidities [e.g., diabetes, hypertension, chronic kidney disease (CKD), hemochromatosis, thalassemia]. For prospective studies, only the baseline data were obtained. We sent three follow-up reminders to investigators who had not responded.

From the studies for which IPD were received, we extracted the data and screened for inclusion in the meta-analysis. We piloted the data extraction by harmonizing the coding of categorical variables (e.g., gender, comorbidities) and their units of measurements, in the case of quantitative variables (Table 2). At this stage, we also compared (variables available in the received datasheets and their original publications) and identified variables common to various studies. When required, we contacted investigators again to request additional variables of interest.

Subsequently, we reextracted the data and checked the files for data integrity in three steps. In step 1, we compared the number of data participants, sex ratio, and the summary data of variables between the data file and its corresponding original paper. In the step 2, we verified the frequency distribution of continuous variables of interest in the individual data files. If required, we contacted the authors in a third step for clarifications. We excluded studies that did not clear the data integrity check.

## 3.3 Participant-level data

From the received data, all participants with an available CC-IMT measurement were selected for pooling from the selected studies. Next, we selected the commonly measured serum iron biomarkers (iron, ferritin, transferrin, and TSAT) and the demographic and laboratory variables: age, sex, body mass index (BMI), smoking status, presence of comorbidities (diabetes, hypertension, CKD, thalassemia,

hemochromatosis), creatinine, hemoglobin, high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), triacylglycerols, fasting glucose, c-reactive protein (CRP), systolic blood pressure (SBP), and diastolic blood pressure (DBP).

When discrete CC-IMT measurements were available on the right and left carotid arteries, the mean was calculated. The data on age, sex, BMI, and the presence of diabetes, hypertension, CKD, thalassemia, and hemochromatosis were used, as indicated, in the original data files. Since the reporting units of the laboratory variables were not uniform, this required harmonization by conversion factors (e.g., mg/dL to mmol/L). Subsequently, we pooled the IPD and added our own data[4] from 323 individuals from the Heidelberg Study on Diabetes and Complications (HEIST-DiC study; https://clinicaltrials.gov, NCT03022721).

At the participant level, we applied the following exclusion criteria: 1) CC-IMT value suggestive of an atherosclerotic plaque[10] (>1.5 mm) 2) diagnosed thalassemia or hemochromatosis 3) TSAT and ferritin values suggestive of possibly hemochromatosis[11] and, 4) CRP>10 mg/dL suggesting overt inflammation[12]. We also analyzed the data for missing values and imputed them for downstream analyses (described below).

## 3.4 Implementation of the ML framework

For the ML analysis, only adult participants (age≥18y) with a valid value for CC-IMT and for one of the iron biomarkers (iron, ferritin, transferrin or TSAT) were included. We converted categorical variables into numerical variables and split the data subsequently into Training and Test subsets stratified based on study (to ensure that proportion of each study in these subsets was comparable to the original dataset). In addition, to avoid information leakage between these subsets, we processed them independently with the following steps: imputation of missing values by bagged trees, removed variables with zero or near-zero variance, centering and scaling of numerical variables.

We implemented a gradient-boosted tree regression model using XGBoost[13]. We used the Training subset further for hyperparameter tuning (using grid search) and performed

a 10-fold cross-validation. We evaluated model performance using Root Mean Squared Error (RMSE) as the primary metric and finalised the best-performing model. We subsequently predicted CC-IMT values on the held-out Test subset and quantified the variables that are of importance for the model prediction. We also used SHAP (SHapley Additive exPlanations[14]) values to interpret the model and to assess feature contributions. For calculation of SHAP values, we used both the Training and Test subsets. The ML pipeline is shown in Figure 2b.

## 3.5 Regression analyses

For the regression analyses, since iron and atherosclerosis parameters show age-specific variations, we used data from adults (age≥18y) for the main analysis. Here, we first tested the association between CC-IMT and each of the iron biomarkers (iron, ferritin, transferrin, and TSAT) by linear mixed model regression in the complete (unimputed) data. We hypothesised that the relationship could be nonlinear, and therefore, flexibly modelled the relationship using spline regression (degree of freedom=4). In addition, since iron metabolism shows strong sex-specific differences, we specified it using an interaction term (e.g. ferritin*sex). Further, to account for differences between the different datasets, we included “study” as a random effect in the model.

To further test the robustness of the observations from the previous step, we conducted multivariable regression analysis between CC-IMT and ferritin or transferrin. Here, we imputed the missing values based on the approach by Gibbs sampler[15,16] and generated multiple imputations (n=5) from a joint multivariable linear-mixed model. For continuous variables, the method considers the relationships between all variables at once, while for categorical variables, the model assumes that they are linked to underlying continuous variables that follow a normal distribution[17]. We performed the regression on the independent imputation draws, using Rubin’s rule[18] and obtained the final imputed results. We included variables from the feature importance in ML analysis as additional covariates for the multivariable regression: smoking (reference=nonsmokers), the presence of diabetes (reference=absence), age, BMI,

creatinine, HDLc, LDLc, triacylglycerols, CRP, hemoglobin, SBP, and DBP. All continuous variables were mean-centered for the analyses[19].

### 3.5.1 Subgroup analysis

We conducted a subgroup analysis for children and adolescents (age< 18y). Here, we also used spline regression (degree of freedom=4) and used sex as an interaction with iron biomarker (as above). However, since not all studies had children and adolescents in their study population, we fitted using linear regression (without including study as a random effect).

## 3.6 UK Biobank

Further analyses were performed in the UK Biobank to determine the associations between hemochromatosis (HFE)-genotype groups and CC-IMT. UK Biobank includes ~500,000 community volunteers aged 39-73 years at baseline assessment (2006-2010) from 22 assessment centers across England, Scotland and Wales (as described elsewhere[20,21]). We included participants genetically similar to the 1000 Genomes project European reference population[22] (the categorization of this population is described elsewhere[23]), with HFE p.C282Y (rs1800562) and HFE p.H63D (rs1799945) genotype data from whole exome sequencing (methods developed by Regeneron[24]). We analyzed a subset of these participants with available carotid ultrasound data from an imaging visit starting in 2014 (n=42,299)[25]). Four CC-IMT variables were available in the UK Biobank imaging study (at 120, 150, 210 and 240 degrees; variable IDs 22671, 22674, 22677, 22680[25]); from these, we calculated an overall mean CC-IMT value and performed linear regression analyses to test associations with C282Y/H63D genotype groups [C282Y$^{(-/-)}$ H63D$^{(+/-)}$; C282Y$^{(-/-)}$ H63D$^{(+/+)}$; C282Y$^{(+/-)}$ H63D$^{(+/-)}$; C282Y$^{(+/-)}$ H63D$^{(-/-)}$; C282Y$^{(+/+)}$ H63D$^{(-/-)}$], compared to those with no mutations [C282Y$^{(-/-)}$H63D$^{(-/-)}$]. Models were stratified by sex, and adjusted for age, assessment centre and ten genetic principal components (to account for genetic stratification). We also performed sensitivity analyses after excluding participants diagnosed with hemochromatosis.

# 4. Results

## 4.1 Process of data collection

We identified a total of 1,032 records via literature search, of which 887 were excluded by screening the title and abstract. The full text of the remaining 145 articles was investigated and 108 publications were selected for the meta-analysis. We contacted the authors of the selected publications, from which we received IPD data from 22 studies (IPD retrieval 20.4%)[26–46]. Of these, we excluded two studies that did not clear the data integrity checks[45,46]. Additionally, we included our own data from the HEIST-DiC study[4]. The flow of the literature search is shown in Figure 1 and the outline of the analysis is shown in Figure 2a.

## 4.2 Study characteristics

Eighteen studies included in the IPD were hospital-based[4,26,27,29–37,39–42,44] and 3 studies were population-based[28,38,43]. Controls were part of the study population in 12 studies[26,27,29–31,35–37,40–43]. The characteristics of studies and variables included in the IPD-MA are shown in Table 1 and Supplementary Table 2.

## 4.3 Participant characteristics

The pooling of all available datasets yielded a total of 10,807 participants. From these, we excluded participants with CC-IMT>1.5 mm (N=47), CRP>10 mg/dL (N=167), possible hemochromatosis[11] (N=27) and those with a diagnosis of thalassemia (N=131) or hemochromatosis (N=76). This resulted in a final pooled participant size of 10,215. Most of the participants were adults except for four studies[34,36,42,43] which had included children and adolescents in their work (age< 18y). Eighteen studies[4,26–29,33–44] included male and female participants, while 3 studies[30–32] included only males in their study population. A study-wise breakdown of participant characteristics is shown in Supplementary Table 3.

### 4.3.1 Adults

The demographics of the adult participants (N=7,523) are shown in Table 2. Here, the proportion of males (N=4,974; 66.12%) was higher than females (N=2,549; 33.88%). Overall, the males were younger, had a higher BMI and a greater proportion of smokers (p=0.009). The proportion of participants with hypertension (p<0.0001) was also higher among males; in line with this observation, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of males were higher (Table 2). On the other hand, more female participants in the cohort had CKD (44.55%; p<0.0001; Table 2). Serum iron, ferritin, and TSAT were higher, while transferrin levels were lower among males than females (Table 2; Supplementary Figures 2-5).

### 4.3.2 Children and Adolescents

Among children and adolescents, age (p=0.131) and BMI (p=0.838) of the participants among both sexes were not different (Table 3). The proportion of smokers was higher among females than males (76% vs 24%; p=0.002). Overall, females had lower hemoglobin levels (p<0.0001). CRP levels were not different between the sexes (p=0.226). Data on the presence of comorbidities were not available for most of the participants (>98%; Table 3). With regards to the iron parameters, males had higher ferritin and transferrin levels while iron and TSAT levels were not different between the sexes (Table 3; Supplementary Figures 2-5)

## 4.4 CC-IMT

In all studies, the CC-IMT was measured using ultrasound, but there were differences in the methods used (Supplementary Table 4). Among the adults, the CC-IMT [median (IQR); mm] of males [0.74 (0.6-0.85)] was higher compared to females [0.71 (IQR 0.6-0.82); p<0.0001; Supplementary Figure 6]. This was also the case among children and adolescents, with higher CC-IMT among males [0.41 (0.37-0.44)] compared to females [0.39 (0.35-0.43); p<0.0001; Supplementary Figure 6].

## 4.5 Missing data

We observed two types of missing values in the IPD data: 1) systematically missing variables were present across studies (since not all studies collected the variables uniformly) 2) sporadically missing values within each study. The proportion of missing values for each variable in the pooled data is shown in Supplementary Table 5. A study-wise breakdown of missing variables is shown in Supplementary Table 6 and an age-categorized breakdown is shown in Supplementary Table 7. The pattern of co-occurrence of missing values across variables is shown in Supplementary Figure 7.

## 4.6 Machine learning

The dataset used for ML contained 5,740 participants and 21 covariates. The Training subset contained 4,306 (75%) participants while the Test subset contained 1,434 (25%) participants. The baseline characteristics between the two subsets were comparable (Supplementary Table 8). The ML model demonstrated moderate predictive performance with an R2 of 0.447, indicating that it explained 44.7% of the variance in the outcome variable; the Root Mean Square Error (RMSE) and the Mean Average Error (MAE) of the model were 0.136 and 0.101, respectively. The feature importance plot shows the contribution of each variable for the prediction of the overall model (Figure 3a). On the other hand, the SHapley Additive exPlanations (SHAP) plot highlights how the variables and their individual values contribute to the prediction (Figure 3b). Together, these plots emphasize the importance of each variable in our ML model's predictions. All the iron biomarkers (transferrin, ferritin, TSAT and iron) were ranked among important predictors of CC-IMT. In addition, age, sex, CRP, creatinine, LDLc, HDLc, hemoglobin, systolic and diastolic BP, triacylglycerols, and smoking were also identified as important features.

## 4.7 Regression analyses

### 4.7.1 Adults

In the analysis of unimputed data, we found that ferritin alone showed a positive effect within specific ranges [131-233 ng/mL: β=0.08, 95% CI (0.002, 0.16), p=0.046; >233

ng/mL: β=0.16, 95% CI (0.04, 0.27), p=0.008]. A significant interactive effect was also observed between females and ferritin with CC-IMT [ferritin>233 ng/mL: β=0.04, 95% CI (0.002, 0.08), p=0.037; Supplementary Table 9]. The main effects of transferrin alone were all non-significant, however negative interactions were noted for transferrin within specific ranges among females [231-263 mg/dL: β=-0.21, 95% CI (-0.43, 0.003), p=0.054; >263 mg/dL: β=-0.73, 95% CI (-1.48, 0.01), p=0.055; Supplementary Table 10]. On the other hand, none of the terms for iron or TSAT (including interactions with sex) showed statistically significant associations with CC-IMT (Supplementary Tables 11-12).

In the multivariable analyses (Tables 4-5), we confirmed potential sex-specific effects at higher levels of ferritin and transferrin. We found that ferritin alone showed a significant effect at a specific range (131-233 ng/mL: β = 0.13, 95% CI [0.02, 0.24], p = 0.038). Further, we found a positive interaction between ferritin with CC-IMT among females with CC-IMT specifically at the higher ranges (>233 ng/mL: β = 0.54, 95% CI [0.11, 0.97], p = 0.015). Although transferrin alone showed no significant effects with CC-IMT, we found significant interactions among females at specific ranges (<199 mg/dL: β= -0.49, 95% CI [-0.93, -0.07], p = 0.05; 199-231 mg/dL: β= -0.3, 95% CI [-0.56, -0.04], p = 0.052; 231-263 mg/dL: β= -0.99, 95% CI [-1.81, -0.17], p = 0.039). The effect of sex alone was nonsignficant in both models. Other significant variables were age (β = 0.14, p < 0.001), diabetes (β = 0.02, p < 0.001), HDL-C (β = -0.006, p = 0.003), LDL-C (β = 0.008, p < 0.001), smoking (β = 0.016, p < 0.001 for former smokers; β = 0.019, p < 0.001 for current smokers), CRP (β = 0.01, p = 0.024), hemoglobin (β = 0.0098, p = 0.010), systolic blood pressure (β = 0.018, p < 0.001), and diastolic blood pressure (β = -0.0087, p = 0.0006); all of these significantly associated with CC-IMT (Tables 4-5).

### 4.7.2 Children and Adolescents

In the subgroup analysis, we found no significant associations between any of the iron biomarkers and CC-IMT among children and adolescents and no notable interactions with sex (Supplementary Tables 13-16).

## 4.8 UK Biobank

Further, we analysed data from 42,299 UK Biobank participants for associations between HFE-genotypes and mean CC-IMT. Here, no statistically significant associations were detected in either males or females between CC-IMT in those with C282Y/H63D genotypes (including C282Y homozygotes) compared to those with no mutations (Supplementary Table 17). The associations remained non-significant in a sensitivity analysis, restricted to participants who were undiagnosed with hemochromatosis (N=42,193).

# 5. Discussion

To investigate the conflicting conclusions of the relationship between iron biomarkers and CC-IMT in previous studies, we conducted and report the first IPD meta-analysis. This meta-analysis includes diversely distributed studies (18 hospital-based and 3 population-based studies) and a study population comprising both adults (N=7,523) and children/adolescents (N=2,691). Although males were over-represented in the study population, the proportion of females in both age groups were sufficient to analyse sex-specific differences. The study participants showed different comorbidities e.g., diabetes, hypertension, and CKD. Therefore, this comprehensive dataset, the largest to date, allows robust exploration to test associations between iron parameters and CC-IMT across age groups and clinical settings. Our analysis approach is also novel since we used two complementary methods (ML and regression). Both, the ML and regression analyses identified iron biomarkers as important predictors of CC-IMT. Additionally, the regression analyses offered insights into sex-specific associations. Overall, the results demonstrate that elevated ferritin and reduced transferrin levels within the reference limits are significant predictors of CC-IMT, particularly in adult females.

Our findings can be interpreted from an ‘iron perspective’: ferritin stores cellular iron and is a well-established marker of body iron stores[47]; transferrin carries iron in the blood and supplies all cell types with the metal. The observed association between elevated

ferritin levels and CC-IMT could be interpreted as supportive of the “iron hypothesis” in atherosclerosis, which suggests that elevated iron stores contribute to oxidative stress and vascular damage[48,49]. This idea is further supported by our current finding that elevated transferrin levels (frequently observed in iron deficiency) are inversely associated with CC-IMT. A recent mendelian randomization study showing that an elevated iron status increases the risk of cardiovascular disease, specifically ischemic stroke provides additional support to this model[50].

As an extension of this idea, the logical argument would be that individuals with genetic iron overload could be at a higher risk of developing cardiovascular disease (CVD). We have previously shown that patients with genetic iron overload conditions (e.g., hemochromatosis or thalassemia major) show elevated markers of vascular dysfunction [Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Adhesion Molecule 1 (VCAM-1)] that correlated positively with non-transferrin-bound-iron (NTBI) in these patients[1,2]. However, phlebotomy treatment of the hemochromatosis patients reverted the increased concentrations of ICAM-1 and VCAM-1[1]. To follow up on these data, we also investigated the UK Biobank for associations between mean CC-IMT and C282Y/H63D genotypes of both sexes, but no significant associations were detected. One explanation for the lack of a significant relationship in the hemochromatosis subgroup in our current analysis could be that the subjects analyzed were well-treated such that NTBI is not present in the blood and NTBI-mediated vascular damage did not occur. Future studies will have to incldue additional biomarkers such as NTBI and hepcidin. In this context, a genome-wide association study by Galesloot et al[51] which showed that polymorphisms predicting higher hepcidin/ferritin ratio were associated with an increased atherosclerosis risk. Unfortunately, data on hepcidin and NTBI were not available in our study to evaluate their associations.

Iron metabolism and inflammation are tightly interconnected processes. Therefore, our findings can also be interpreted from an ‘inflammation perspective’. Inflammation is known to aggravate atherosclerosis[52]. Ferritin is a well-known acute phase protein, which is induced in response to inflammation. Similarly, transferrin levels are reduced in inflammatory conditions[53]. Although, we have excluded inviduals with CRP>10 mg/dL in

our analysis, we canot completely exclude low-grade inflammation as a driver of increased CC-IMT. Thus, the opposing associations of ferritin and transferrin with CC-IMT could also be an epiphenomenon to inflammation. However, in inflammatory states, we would expect hypoferremia due to iron redistribution into reticuloendothelial macrophages[54]. But, CC-IMT was not associated with reduced serum iron levels in our analysis, providing a counterargument for an inflammatory response of ferritin and transferrin.

It is well established that biological sex influences the risk for CVD[55]. Although the overall prevalence of CVD is higher among males, several studies show a higher risk of mortality and morbidity in females due to CVD, particularly in the presence of common risk factors and comorbidities[56,57]. Additional risk factors specific for females include hormones, pregnancy and reproductive health specific for women (e.g. menstruation, pregnancy-associated disorders etc). These findings are reflected in the Americal College of Cardiology recommendations on the primary prevention of CVD for women[58]. Importantly, iron homeostasis is also influenced by the female sexual hormones. For example, estrogen inhibits[59] and progesterone[60] activates hepcidin expression. Therefore, this current study adds to the body of evidence on sex-differences in CVD. Interestingly, our recent work also detected a positive nonlinear association between ferritin and peripheral arterial disease in certain ferritin ranges specifically in females (48–97 ng/mL: OR 14.59, 95% CI 1.6–135.93, P = 0.019; 98–169 ng/mL: OR 171.07, 95% CI 1.27–23404, P = 0.039)[61]. Unfortunately, we were unable to adjust for effects of hormonal status or menstruation status in this study due to the unavailability of data. Further, whether these reproductive hormones also affect the production of other liver-expressed proteins, such as ferritin or transferrin is unclear.

The strengths of our study include the comprehensive analysis of iron biomarkers with CC-IMT, thereby providing a rather complete picture of the role of systemic iron status. For the analysis, we applied both ML and regression in our approach. A key advantage of the ML approach is its ability to capture complex, nonlinear interactions between predictors. On the other hand, regression results are more interpretable due to their straightforward effect sizes and significance values and thus providing hypothesis-

driven insights. Despite its advantages, the ML approach has limitations, including its reliance on large datasets for optimal performance and the potential for overfitting, particularly if not properly tuned. Additionally, ML models can be seen as “black boxes,” making it challenging to derive explicit causal inferences or explainability in clinical decision-making. Conversely, while regression models provide interpretable and statistically robust associations, to some extent, they assume linearity. Furthermore, regression models are susceptible to multicollinearity and require prespecified assumptions (such as defining covariates), which can limit their flexibility in identifying novel predictive patterns. In our current study, we identified variables of importance from ML and included them as covariates for the regression analyses and therefore, have integrated the two approaches. This complementary use of both methods strengthens the validity of our findings and provides a comprehensive perspective on cardiovascular risk assessment. An additional advantage of this meta-analysis is that it has achieved a good participant mix with studies from different geographical locations, a range of age groups (adults and children and adolescents), and common comorbidities such as CKD, diabetes, and hypertension. Thus, we believe that the findings are generalizable across healthy individuals, disease states and in different age groups.

The following limitations should however be considered when interpreting our findings. First, data retrieval for the IPD was incomplete, as we received only 20.4% of the published data despite our best efforts. We also had a significant proportion of missing data, both systematically across studies and sporadically within each study. Furthermore, it is essential to recognize that the data availability for these variables was not uniform across all studies; for example, we have not adjusted the models for the different treatments (e.g., medications for diabetes, lipid-lowering, dialysis for CKD, phlebotomy for hemochromatosis etc) which could affect the CC-IMT outcome. It is worth noting that the data on additional iron biomarkers (hepcidin, NTBI) or menstrual and hormonal status were not available. In addition, the study population also does not represent all ethnicities, so we have not estimated effects due to these. Further, the following sources of bias may affect our conclusions. The differences in the ultrasound methodology (Supplementary Table 4) used for measuring and calculating the CC-IMT

across studies e.g., location of the measurement, the method used for calculating average CC-IMT value, transducer frequency, and the different personnel involved; these differences could contribute to low/unclear risk of assessment bias. Additionally, our study is cross-sectional and does not assess the temporal relationship between the parameters; therefore, causality cannot be implied. Finally, since the study relied on published data, an element of publication bias cannot be excluded, as studies with non-significant results may remain unpublished and therefore, undiscovered.

## 6. Conclusion

Our current results, demonstrate that iron biomarkers (specifically ferritin and transferrin) are non-linearly associated with CC-IMT specifically in females. Because these iron biomarkers are additionally regulated in inflammatory states, this complicates their interpretation in the context of atherosclerosis. We propose that inflammation and iron metabolism are likely interconnected in their effects on vascular health. Future studies may want to consider inflammatory markers alongside iron status indicators to better disentangle their specific contributions to atherosclerosis. We consider our findings exploratory to drive further research addressing the underlying mechanisms that could explain these associations.

## 7. Ethics statement

All primary studies were approved by the local Ethics committees. All participants were included in the study according to the guidelines of the local ethics committees following written informed consent to participate. The North West Multi-Centre Research Ethics Committee (Research Ethics Committee reference 11/NW/0382) approved UK Biobank, and all participants provided their written informed consent at baseline. All research was conducted in accordance with both the Declarations of Helsinki and Istanbul.

## 8. Funding

No financial support was received for this meta-analysis. MUM acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG) (SFB1118; GRK 2727; FerrOs - FOR5146; Ferroptosis SPP2306: Project No.461704553) and the Federal Ministry of Education and Research (NephrESA Nr 031L0191C; Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL); Project No. FKZ 82DZL004A1). JLA is funded by a National Institute for Health and Care Research Advanced Fellowship (NIHR301844).

## 9. Author contributions

Anand Ruban Agarvas: Conceptualization, Methodology, Software, Formal analysis, Investigation, Data curation, Writing- Original draft, Visualization, Project administration

Richard Sparla: Investigation, Writing - Review

Janice L. Atkins (for UK Biobank): Formal analysis, Investigation, Writing- Original draft

José Manuel Fernández-Real, José María Moreno-Navarrete, Abel López-Bermejo, Judit Bassols, Krystyna Pawlak, Dariusz Pawlak, Claudia Altamura, H M Dvořáková, Ebru Asicioglu, Jovana Kusic Milicevic, Michael Knoflach, Christoph Hochmayr, Petr Syrovatka, Peter Riško, Silvia Lai, Todd Anderson: Data curation, Investigation, Writing - Review

Dorota Formanowicz, Jose M Valdivielso, Pavel Kraml, Luca Valenti: Data curation, Investigation, Writing - Review & Editing

Martina U. Muckenthaler: Supervision, Writing - Review & Editing, Project administration

## 10. Acknowledgement

We thank the participants of all included studies. We also acknowledge the contributions of investigators and their efforts without which this data collection would not have been possible (Dr. Stefan Kopf, Dr. Rashid Merchant, Dr. Amina Abdel-Salam, Dr. Peter Risko, Dr. Tessel E. Galesloot, Dr. Dorine Swinkles, Dr. George Hahalis). We acknowledge Dr. Tiago JS Lopes's inputs on the development of the machine learning model and Svenja Elizabeth Seide's contributions to data preprocessing and imputation. Part of this research was conducted using the UK Biobank resource, under application 14631. We thank the UK Biobank participants and coordinators. This work used data provided by patients and collected by the NHS as part of their care and support. Copyright © (2023), NHS England. Re-used with the permission of the NHS England and UK Biobank. All rights reserved. This research also used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation. This study was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

## 11. Conflict of interest

None to declare.

## 12. Data and Code Availability Statement

Part of the data (subject to data sharing restrictions) may be available from authors upon reasonable request. Codes used for data analysis and visualization are accessible here: https://github.com/griffindoc/imt

# 14. Legends

Figure 1. The outline of the study and analysis

Figure 2. a) The flow of literature in the IPD. b) The machine learning pipeline

Figure 3. a) Variables of importance identifed in the machine learning prediciton b) SHAPley plot of the variables contributing to the model performance

Table 1. Characteristics of studies included in the IPD-MA

Table of the characteristics of studies that provided the IPD and included in the meta-analysis.

Table 2. Characteristics of adult participants

The demographics of the adult participants (age≥18y) stratified by sex are shown. For continuous variables, the summary data are shown as Median (IQR) while for categorical variables, the data are represented as N (%). P-values as calculated by Wilcoxon rank sum test (for continuous variables) or Pearson's Chi-Squared test (for categorical variables); significant P-values are highlighted in bold. Missing data are shown as N (%).

BMI: Body Mass Index, HDLc: High-Density Lipoprotein, LDLc: Low-Density Lipoprotein, CRP: C-reactive protein, CKD: Chronic Kidney Disease, CC-IMT: Carotid Intima-Media Thickness, TSAT: Transferrin Saturation, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure

Table 3. Characteristics of children and adolescents

The demographics of the children and adolescent participants (age< 18y) stratified by sex are shown. For continuous variables, the summary data are shown as Median (IQR) while for categorical variables, the data are represented as N (%). P-values as calculated by the Wilcoxon rank sum test (for continuous variables) or Pearson's Chi-

Squared test (for categorical variables); significant P-values are highlighted in bold. Missing data are shown as N (%).

BMI: Body Mass Index, HDLc: High-Density Lipoprotein, LDLc: Low-Density Lipoprotein, CRP: C-reactive protein, CKD: Chronic Kidney Disease, CC-IMT: Carotid Intima-Media Thickness, TSAT: Transferrin Saturation, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure

Table 4. Multivariable regression analysis of ferritin and CC-IMT

We flexibly modelled the relationship between ferritin and CC-IMT using spline regression (degree of freedom=4). In addition, we tested the associations between ferritin and CC-IMT for differences due to sex- by using an interaction term (ferritin*sex; Males as reference). All continuous variables were mean-centered for the analyses. BMI: Body Mass Index, HDLc: High-Density Lipoprotein, LDLc: Low-Density Lipoprotein, CRP: C-reactive protein, CC-IMT: Carotid Intima-Media Thickness, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure.

Table 5. Multivariable regression analysis of transferrin and CC-IMT

We flexibly modelled the relationship between transferrin and CC-IMT using spline regression (degree of freedom=4). In addition, we tested the associations between transferrin and CC-IMT for differences due to sex- by using an interaction term (transferrin *sex; Males as reference). All continuous variables were mean-centered for the analyses. BMI: Body Mass Index, HDLc: High-Density Lipoprotein, LDLc: Low-Density Lipoprotein, CRP: C-reactive protein, CC-IMT: Carotid Intima-Media Thickness, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure.

Supplementary files

Supplementary File 1. Study protocol as published in PROSPERO database

Supplementary File 2. PRISMA-IPD checklist

Supplementary Figure 1. Scheme used for data requests in the study

Supplementary Figure 2. Rain cloud plots of serum iron categorised by age group and sex

Supplementary Figure 3. Rain cloud plots of serum ferritin categorised by age group and sex

Supplementary Figure 4. Rain cloud plots of serum transferrin categorised by age group and sex

Supplementary Figure 5. Rain cloud plots of serum TSAT categorised by age group and sex

Supplementary Figure 6. Rain cloud plots of CC-IMT categorised by age group and sex

Supplementary Figure 7. Figure showing the pattern of co-occurrences and instances of missing values in the dataset

Supplementary Table 1. List of R packages used in the analysis

Supplementary Table 2. Variables included in IPD-MA

Table of the variables, included in the IPD with a breakdown of the number of data points, number of studies that contained a variable and the sources.

Supplementary Table 3. Table of the study-wise breakdown of participant characteristics

Supplementary Table 4. Methodological differences in CC-IMT measurement

Supplementary Table 5. Table of a breakdown of the proportion of missing values for each variable in the pooled data

Supplementary Table 6. Table of a studywise breakdown of the proportion of missing values for each variable

Supplementary Table 7. Table of a breakdown of the proportion of missing values for each variable categorised by age group

Supplementary Table 8. Comparison of baseline characteristics between the Training and Test subsets used for Machine Learning

Supplementary Table 9. Regression output Ferritin vs CC-IMT in adults

We fitted a linear mixed model in (estimated using REML and nloptwrap optimizer) to predict CC-IMT with ferritin and sex (formula: imt ~ 1 + ns(ferritin, df = 4) * sex). The model included study as random effect (formula: ~1 | study). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 10. Regression output Transferrin vs CC-IMT in adults

We fitted a linear mixed model (estimated using REML and nloptwrap optimizer) to predict CC-IMT with transferrin and sex (formula: imt ~ 1 + ns(transferrin, df = 4) * sex). The model included study as random effect (formula: ~1 | study). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 11. Regression output TSAT vs CC-IMT in adults

We fitted a linear mixed model (estimated using REML and nloptwrap optimizer) to predict CC-IMT with TSAT and sex (formula: imt ~ 1 + ns(TSAT, df = 4) * sex). The model included study as random effect (formula: ~1 | study). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 12. Regression output Iron vs CC-IMT in adults

We fitted a linear mixed model (estimated using REML and nloptwrap optimizer) to predict CC-IMT with iron and sex (formula: imt ~ 1 + ns(iron, df = 4) * sex). The model

included study as random effect (formula: ~1 | study). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 13. Regression output Ferritin vs CC-IMT in children and adolescents

We fitted a linear model (estimated using maximum likelihood) to predict CC-IMT with ferritin and sex (formula: imt ~ 1 + ns(ferritin, df = 4) * sex). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 14. Regression output TSAT vs CC-IMT in children and adolescents

We fitted a linear model (estimated using maximum likelihood) to predict CC-IMT with TSAT and sex (formula: imt ~ 1 + ns(TSAT, df = 4) * sex). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 15. Regression output Iron vs CC-IMT in children and adolescents

We fitted a linear model (estimated using maximum likelihood) to predict CC-IMT with iron and sex (formula: imt ~ 1 + ns(iron, df = 4) * sex). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 16. Regression output Transferrin vs CC-IMT in children and adolescents

We fitted a linear model (estimated using maximum likelihood) to predict CC-IMT with transferrin and sex (formula: imt ~ 1 + ns(transferrin, df = 4) * sex). Complete (unimputed) data was used. CI = Confidence Interval

Supplementary Table 17. Associations between hemochromatosis HFE-genotypes and mean CC-IMT in the UK Biobank data

Restricted to UK Biobank participants of European genetic ancentry. Models stratified by sex and adjusted for age, assessment centre and first ten genetic principle components. Mean of CC-IMT calculated from different measurements at 120/150/210/240 degrees.

Supplementary file 2. PRISMA-IPD checklist


1. Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, Silva AMN, Spaich S, Seide SE, Sparla R, Hentze MW, Muckenthaler MU. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur Heart J 2020;41:2681–2695.

2. Vinchi F, Sparla R, Passos ST, Sharma R, Vance SZ, Zreid HS, Juaidi H, Manwani D, Yazdanbakhsh K, Nandi V, Silva AMN, Agarvas AR, Fibach E, Belcher JD, Vercellotti GM, Ghoti H, Muckenthaler MU. Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in transfusion-dependent patients with haemolytic anaemias. British Journal of Haematology 2021;193:637–658.

3. Formanowicz D, Radom M, Rybarczyk A, Formanowicz P. The role of Fenton reaction in ROS-induced toxicity underlying atherosclerosis modeled and analyzed using a Petri net-based approach. Biosystems 2018;165:71–87.

4. Agarvas AR, Kopf S, Thalmann P, Fernández-Real JM, Nawroth P, Muckenthaler MU. Markers of systemic iron status show sex-specific differences in peripheral artery disease: A cross-sectional analysis HEIST-DiC and NHANES participants. medRxiv 2023:2023.08.21.23293418.

5. Oord SC van den, Sijbrands EJ, Kate GL ten, Klaveren D van, Domburg RT van, Steen AF van der, Schinkel AF. Carotid intima-media thickness for cardiovascular risk assessment: Systematic review and meta-analysis. Atherosclerosis 2013;228:1–11.

6. Polak JF, O'Leary DH. Carotid intima-media thickness as surrogate for and predictor of CVD. Glob Heart 2016;11:295–312 e3.

7. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, Rovers M. Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use. PLOS Medicine 2015;12:e1001855.

8. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF, Group P-ID. Preferred reporting items for systematic review and meta-analyses of individual participant data: The PRISMA-IPD statement. JAMA 2015;313:1657–1665.

9. R Core Team 2023. R core team (2023). 2023.

10. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Kownator S, Prati P, Rundek T, Taylor A, Bornstein N, Csiba L, Vicaut E, Woo KS, Zannad F, Advisory Board of the 3rd Watching the Risk Symposium th ESC. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004;18:346–349.

11. Zoller H, Schaefer B, Vanclooster A, Griffiths B, Bardou-Jacquet E, Corradini E, Porto G, Ryan J, Cornberg M. EASL Clinical Practice Guidelines on haemochromatosis. Journal of Hepatology 2022;77:479–502.

12. Yeh ETH, Willerson JT. Coming of Age of C-Reactive Protein: Using Inflammation Markers in Cardiology. Circulation 2003;107:370–371.

13. Chen T, Guestrin C. KDD '16: The 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. San Francisco California USA: ACM; 2016. p785–794.

14. Lundberg S, Lee S-I. A unified approach to interpreting model predictions. 2017.

15. Yucel RM. Random-covariances and mixed-effects models for imputing multivariate multilevel continuous data. Stat Modelling 2011;11:351–370.

16. Schafer JL, Yucel RM. Computational strategies for multivariate linear mixed-effects models with missing values. Journal of Computational and Graphical Statistics 2002;11:437–457.

17. Carpenter RJ, Kenward MG. Mutlilevel imputation. 2013. p203–228.

18. Rubin DB. Multiple imputation for nonresponse in surveys. 1987.

19. Enders CK, Tofighi D. Centering predictor variables in cross-sectional multilevel models: A new look at an old issue. Psychological Methods 2007;12:121–138.

20. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine 2015;12:e1001779.

21. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. American Journal of Epidemiology 2017;186:1026–1034.

22. Committee on the use of race, ethnicity, and ancestry as population descriptors in genomics research

23. Casanova F, Tian Q, Atkins JL, Wood AR, Williamson D, Qian Y, Zweibaum D, Ding J, Melzer D, Ferrucci L, Pilling LC. Iron and risk of dementia: Mendelian randomisation analysis in UK Biobank. Journal of Medical Genetics 2024.

24. Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-Jauregui C, Khalid S, Ye B, Banerjee N, Li AH, O'Dushlaine C, Marcketta A, Staples J, Schurmann C, Hawes A, Maxwell E, Barnard L, Lopez A, Penn J, Habegger L, Blumenfeld AL, Bai X, O'Keeffe S, Yadav A, Praveen K, Jones M, Salerno WJ, Chung WK, Surakka I, Willer CJ, Hveem K, Leader JB, Carey DJ, Ledbetter DH, Geisinger-Regeneron DiscovEHR Collaboration, Cardon L, Yancopoulos GD, Economides A, Coppola G, Shuldiner AR, Balasubramanian S, Cantor M, Regeneron Genetics Center, Nelson MR, Whittaker J, Reid JG, Marchini J, Overton JD, Scott RA, Abecasis GR, Yerges-Armstrong L, Baras A. Exome sequencing and characterization of 49,960 individuals in the UK Biobank. Nature 2020;586:749–756.

25. UK Biobank. Carotid ultrasound measures

26. Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients. Am J Nephrol 2006;26:497–502.

27. Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, Karakantza M, Kourakli A, Adamopoulos S, Tselepis AD, Grapsas N, Siablis D, Zoumbos NC, Alexopoulos D. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis 2008;198:448–457.

28. Anderson TJ, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H, Hildebrand K, Fung M, Verma S, Lonn EM. Microvascular function predicts cardiovascular events in primary prevention: Long-term results from the firefighters and their endothelium (FATE) study. Circulation 2011;123:163–169.

29. Altamura C, Squitti R, Pasqualetti P, Gaudino C, Palazzo P, Tibuzzi F, Lupoi D, Cortesi M, Rossini PM, Vernieri F. Ceruloplasmin/transferrin system is related to clinical status in acute stroke. Stroke 2009;40:1282–1288.

30. Risko P, Platenik J, Buchal R, Potockova J, Kraml PJ. The labile iron pool in monocytes reflects the activity of the atherosclerotic process in men with chronic cardiovascular disease. Physiol Res 2017;66:49–61.

31. Risko P, Platenik J, Buchal R, Potockova J, Kraml PJ. Long-term donors versus non-donor men: Iron metabolism and the atherosclerotic process. Atherosclerosis 2018;272:14–20.

32. Syrovatka P, Kraml P, Hulikova K, Fialova L, Vejrazka M, Crkovska J, Potockova J, Andel M. Iron stores are associated with asymptomatic atherosclerosis in healthy men of primary prevention. Eur J Clin Invest 2011;41:846–853.

33. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Rametta R, Fargion S, Fracanzani AL. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011;21:568–575.

34. Prats-Puig A, Moreno M, Carreras-Badosa G, Bassols J, Ricart W, Lopez-Bermejo A, Fernandez-Real JM. Serum ferritin relates to carotid intima-media thickness in offspring of fathers with higher serum ferritin levels. Arterioscler Thromb Vasc Biol 2016;36:174–180.

35. Merchant RH, Chate S, Ahmed J, Ahmad N, Karnik A, Jankaria B. Evaluation of carotid artery dynamics & correlation with cardiac & hepatic iron in beta-thalassaemia patients. Indian J Med Res 2016;143:443–448.

36. Dvorakova HM, Szitanyi P, Dvorak P, Janda J, Seeman T, Zieg J, Lanska V, Kotaska K, Pitha J. Determinants of premature atherosclerosis in children with end-stage renal disease. Physiol Res 2012;61:53–61.

37. Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener C. Fibroblast growth factor-23 levels are associated with uric acid but not carotid intima media thickness in renal transplant recipients. Transplant Proc 2014;46:180–183.

38. Galesloot TE, Holewijn S, Kiemeney LA, Graaf J de, Vermeulen SH, Swinkels DW. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler Thromb Vasc Biol 2014;34:446–456.

39. Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fernández E. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrology 2014;15:168.

40. Formanowicz D, Wanic-Kossowska M, Pawliczak E, Radom M, Formanowicz P. Usefulness of serum interleukin-18 in predicting cardiovascular mortality in patients with chronic kidney diseasesystems and clinical approach. Sci Rep 2015;5:18332.

41. Lai S, Dimko M, Galani A, Coppola B, Innico G, Frassetti N, Mazzei ED, Mariotti A. Early markers of cardiovascular risk in chronic kidney disease. Ren Fail 2015;37:254–261.

42. Abaza SE, Abdel-Salam A, Baz AA, Mohamed AA. Carotid doppler ultrasonography as a screening tool of early atherosclerotic changes in children and young adults with beta-thalassemia major. J Ultrasound 2017;20:301–308.

43. Bernar B, Gande N, Stock KA, Staudt A, Pechlaner R, Geiger R, Griesmacher A, Kiechl S, Knoflach M, Kiechl-Kohlendorfer U, Early Vascular Aging Study G. The tyrolean early vascular ageing-study (EVA-tyrol): Study protocol for a non-randomized controlled trial : Effect of a cardiovascular health promotion program in youth, a prospective cohort study. BMC Cardiovasc Disord 2020;20:59.

44. Kusic Milicevic J, Vidakovic R, Markovic R, Andjelkovic Apostolovic M, Korac M, Trbojevic Stankovic J, Jemcov T, Neskovic AN, Dragovic G. Cardiovascular risk assessment and coronary artery calcification burden in asymptomatic patients in the initial years of hemodialysis. Ther Apher Dial 2022;26:64–70.

45. Hanafy AS, Seleem WM, El-Kalla F, AbdAlkhalik Basha M, Abd-Elsalam S. Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. Diabetes Metab Syndr 2019;13:2272–2278.

46. Nassef S, El Shenoufy M, Rawi R, El Demerdash D, Hassan M, Mustafa H, Mattar M, El Husseiny N. Assessment of atherosclerosis in peripheral and central circulation in adult beta thalassemia intermedia patients by color doppler ultrasound: Egyptian experience. J Vasc Res 2020;57:206–212.

47. DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR. Cytokine signatures in atherosclerotic claudicants. Journal of Surgical Research 2003;111:215–221.

48. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293–1294.

49. Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochimica Et Biophysica Acta 2009;1790:718–723.

50. Barad A, Clark AG, Pressman EK, O'Brien KO. Associations Between Genetically Predicted Iron Status and Cardiovascular Disease Risk: A Mendelian Randomization Study. Journal of the American Heart Association 2024;13:e034991.

51. Galesloot TE, Janss LL, Burgess S, Kiemeney LALM, Den Heijer M, De Graaf J, Holewijn S, Benyamin B, Whitfield JB, Swinkels DW, Vermeulen SH. Iron and hepcidin as risk factors in atherosclerosis: what do the genes say? BMC Genetics 2015;16:79.

52. Baek JH, Yalamanoglu A, Gao Y, Guenster R, Spahn DR, Schaer DJ, Buehler PW. Iron accelerates hemoglobin oxidation increasing mortality in vascular diseased guinea pigs following transfusion of stored blood. JCI insight 2017;2.

53. Fleck A. Clinical and nutritional aspects of changes in acute-phase proteins during inflammation. Proceedings of the Nutrition Society 1989;48:347–354.

54. Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, Hentze MW, Muckenthaler MU. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood 2015;125:2265–2275.

55. Rajendran A, Minhas AS, Kazzi B, Varma B, Choi E, Thakkar A, Michos ED. Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women. Atherosclerosis 2023;384:117269.

56. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035–2038.

57. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet (London, England) 2011;378:1297–1305.

58. Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, Michos ED, Minissian M, Pepine C, Vaccarino V, Volgman AS, ACC CVD Womens Committee Members. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. Journal of the American College of Cardiology 2020;75:2602–2618.

59. Yang Q, Jian J, Katz S, Abramson SB, Huang X. 17β-Estradiol Inhibits Iron Hormone Hepcidin Through an Estrogen Responsive Element Half-Site. Endocrinology 2012;153:3170–3178.

60. Li X, Rhee DK, Malhotra R, Mayeur C, Hurst LA, Ager E, Shelton G, Kramer Y, McCulloh D, Keefe D, Bloch KD, Bloch DB, Peterson RT. Progesterone receptor membrane component-1 regulates hepcidin biosynthesis. The Journal of Clinical Investigation 2016;126:389–401.

61. Ruban Agarvas A, Kopf S, Lopes TJS, Atkins JL, Thalmann P, Fernández-Real JM, Nawroth P, Muckenthaler MU. Iron biomarkers predict peripheral artery disease in females. Atherosclerosis 2025;402:119111.

62. Fernandez-Real JM, Puig J, Serrano M, Sabater M, Rubio A, Moreno-Navarrete JM, Fontan M, Casamitjana R, Xifra G, Ortega FJ, Salvador J, Fruhbeck G, Ricart W. Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations. PLoS One 2013;8:e58961.

**Table 1. Characteristics of studies included in the IPD-MA**

| Study | Participant source | Controls | N (%) | Study population |
|---|---|---|---|---|
| Arroyo et al.[40] | Hospital-based | Yes | 3,004 (27.8%) | Participants with CKD and controls with a glomerular filtration rate >60ml/min/m2 |
| Valenti et al.[34] | Hospital-based | No | 506 (4.68%) | Participants with nonalcoholic fatty liver disease. In a subset of participants, the presence of C282Y and H63D HFE mutations were analysed |
| Abaza et al.[43] | Hospital-based | Yes | 42 (0.39%) | Participants with β-thalassemia major and healthy controls |
| Pawlak et al.[27] | Hospital-based | Yes | 26 (0.24%) | Participants with CKD on hemodialysis |
| Anderson et al.[29] | Population-based | No | 1,578 (14.6%) | Healthy males |
| Altamura et al.[30] | Hospital-based | Yes | 41 (0.38%) | Individuals who had acute stroke and elderly controls without a history of neurological or vascular disease |
| Asicioglu et al.[38] | Hospital-based | Yes | 36 (0.33%) | Healthy volunteers and individuals who had a kidney transplant |
| Fernandez-Real et al.[57] | Population-based | No | 79 (0.73%) | Healthy volunteers |
| Merchant et al.[36] | Hospital-based | Yes | 78 (0.72%) | Participants with β-thalassemia major and controls. |
| Risko et al.[31] | Hospital-based | Yes | 161 (1.49%) | Healthy individuals and individuals with cardiovascular disease. |
| Risko et al.[32] | Hospital-based | Yes | 161 (1.49%) | Healthy men (long-term blood donors and non-donors). |
| Syrovatka et al.[33] | Hospital-based | No | 161 (1.49%) | Healthy males |
| Formanowicz et al.[41] | Hospital-based | Yes | 158 (1.46%) | Healthy controls and individuals with CKD |

| | | | | |
|---|---|---|---|---|
| Lai et al.[42] | Hospital-based | Yes | 68 (0.63%) | Healthy controls and individuals with CKD |
| Galesloot et al.[39] | Population-based | No | 1,517 (14.04%) | Participants of the Nijmegen Biomedical study |
| Milicevic et al.[45] | Hospital-based | No | 60 (0.56%) | Participants with CKD on haemodialysis |
| Hahalis et al.[28] | Hospital-based | Yes | 70 (0.65%) | Healthy volunteers and participants with β-thalassemia major |
| Dvarakova et al.[37] | Hospital-based | Yes | 59 (0.55%) | children with CKD and healthy controls |
| Prats-Puig et al.[35] | Hospital-based | No | 854 (7.9%) | Healthy children |
| Bernar et al.[44] | Population-based | No | 2,102 (19.45%) | Healthy adolescents |

| Table 2. Characteristics of Adult participants | | | | | |
|---|---|---|---|---|---|
| **Characteristic** | **Missing** | **Overall N = 7,523[1]** | **Males N = 4,974[1]** | **Females N = 2,549[1]** | **p-value[2]** |
| **Age (years)** | 0 (0%) | 57 (47, 65) | 55 (46, 64) | 58 (50, 66) | **<0.001** |
| **BMI (kg/sq.m)** | 152 (2.0%) | 27.2 (24.6, 30.2) | 27.5 (25.2, 30.2) | 26.4 (23.4, 30.3) | **<0.001** |
| **Smoking** | | | | | |
| **Nonsmokers** | 328 (4.4%) | 3,972 (55%) | 2,600 (54%) | 1,372 (58%) | **0.009[c]** |
| **Former Smokers** | | 1,912 (27%) | 1,313 (27%) | 599 (25%) | |
| **Current Smokers** | | 1,311 (18%) | 907 (19%) | 404 (17%) | |
| **Diabetes** | | | | | |
| **No Diabetes** | 901 (12%) | 5,480 (83%) | 3,678 (83%) | 1,802 (83%) | >0.9[c] |
| **Diabetes** | | 1,142 (17%) | 767 (17%) | 375 (17%) | |
| **Hypertension** | | | | | |
| **No hypertension** | 2,322 (31%) | 1,717 (33%) | 837 (28%) | 880 (40%) | **<0.001[c]** |
| **Hypertension** | | 3,484 (67%) | 2,150 (72%) | 1,334 (60%) | |
| **SBP (mm/Hg)** | 310 (4.1%) | 132 (120, 145) | 132 (121, 145) | 130 (118, 145) | **<0.001** |
| **DBP (mm/Hg)** | 310 (4.1%) | 80 (73, 88) | 80 (75, 88) | 78 (70, 86) | **<0.001** |
| **CKD** | | | | | |
| **No CKD** | 2,490 (33%) | 2,467 (49%) | 1,999 (55%) | 468 (33%) | **<0.001[c]** |
| **CKD** | | 2,566 (51%) | 1,606 (45%) | 960 (67%) | |
| **Anemia** | | | | | |
| **No Anemia** | 3,533 (47%) | 2,737 (69%) | 1,573 (66%) | 1,164 (72%) | **<0.001[c]** |
| **Anemia** | | 1,253 (31%) | 804 (34%) | 449 (28%) | |
| **Hemoglobin (g/dL)** | 3,532 (47%) | 13.40 (12.10, 14.70) | 14.00 (12.40, 15.20) | 12.80 (11.90, 13.80) | **<0.001** |
| **Creatinine (mg/dL)** | 3,156 (42%) | 1.05 (0.86, 1.83) | 1.22 (0.96, 2.10) | 0.89 (0.77, 1.49) | **<0.001** |
| **HDLc (mg/dL)** | 784 (10%) | 49 (41, 59) | 46 (39, 55) | 57 (47, 68) | **<0.001** |
| **LDLc (mg/dL)** | 882 (12%) | 118 (94, 145) | 118 (94, 143) | 120 (95, 148) | **0.005** |
| **Triacylglycerols (mg/dL)** | 512 (6.8%) | 124 (88, 180) | 127 (89, 186) | 119 (84, 170) | **<0.001** |
| **CRP (mg/dL)** | 5,476 (73%) | 4.00 (1.30, 4.00) | 4.00 (1.29, 4.00) | 4.00 (1.40, 4.00) | 0.14 |
| **CC-IMT (mm)** | 107 (1.4%) | 0.73 (0.60, 0.84) | 0.74 (0.60, 0.85) | 0.71 (0.60, 0.82) | **<0.001** |

| | | | | | |
|---|---|---|---|---|---|
| **Iron (µM)** | 4,271 (57%) | 17.0 (14.0, 21.0) | 18.0 (14.0, 22.0) | 16.0 (12.5, 19.9) | **<0.001** |
| **Ferritin (ng/mL)** | 1,786 (24%) | 131 (66, 233) | 156 (87, 260) | 89 (45, 171) | **<0.001** |
| **Transferrin (g/L)** | 4,594 (61%) | 231 (199, 263) | 230 (199, 261) | 233 (199, 269) | **0.012** |
| **TSAT (%)** | 2,713 (36%) | 28 (22, 35) | 30 (23, 37) | 26 (20, 32) | **<0.001** |

[1]Median (Q1, Q3); n (%)

[2]Wilcoxon rank sum test; Pearson's Chi-squared test[c]

**Table 3: Characteristics of children and adolescents**

| Characteristic | Missing | Overall N = 2,691[1] | Males N = 1,241[1] | Females N = 1,450[1] | p-value[2] |
|---|---|---|---|---|---|
| **Age (years)** | 0 (0%) | 15.5 (10.2, 16.5) | 15.4 (9.7, 16.4) | 15.6 (10.8, 16.5) | 0.13 |
| **BMI (kg/sq.m)** | 12 (0.4%) | 20.7 (18.4, 23.3) | 20.8 (18.1, 23.4) | 20.6 (18.5, 23.1) | 0.8 |
| **Smoking** | | | | | |
| **Nonsmokers** | 887 (33%) | 1,307 (72%) | 593 (76%) | 714 (70%) | **0.002** |
| **Former Smokers** | | 0 (0%) | 0 (0%) | 0 (0%) | |
| **Current Smokers** | | 497 (28%) | 185 (24%) | 312 (30%) | |
| **Diabetes** | | | | | |
| **No Diabetes** | 2,687 (100%) | 4 (100%) | 3 (100%) | 1 (100%) | >0.9 |
| **Diabetes** | | 0 (0%) | 0 (0%) | 0 (0%) | |
| **Hypertension** | | | | | |
| **No HT** | 2,686 (100%) | 4 (80%) | 3 (75%) | 1 (100%) | >0.9 |
| **HT** | | 1 (20%) | 1 (25%) | 0 (0%) | |
| **SBP (mm/Hg)** | 18 (0.7%) | 117 (108, 127) | 121 (109, 131) | 115 (107, 123) | **<0.001** |
| **DBP (mm/Hg)** | 18 (0.7%) | 68 (62, 74) | 67 (61, 73) | 69 (63, 75) | **<0.001** |
| **CKD** | | | | | |
| **No CKD** | 2,641 (98%) | 22 (44%) | 10 (42%) | 12 (46%) | 0.7 |
| **CKD** | | 28 (56%) | 14 (58%) | 14 (54%) | |
| **Anemia** | | | | | |
| **No Anemia** | 70 (2.6%) | 2,556 (98%) | 1,193 (99%) | 1,363 (97%) | **<0.001** |
| **Anemia** | | 65 (2.5%) | 16 (1.3%) | 49 (3.5%) | |
| **Hemoglobin (g/dL)** | 70 (2.6%) | 13.90 (13.00, 14.90) | 14.70 (13.30, 15.70) | 13.60 (12.90, 14.20) | **<0.001** |
| **Creatinine (mg/dL)** | 9 (0.3%) | 0.75 (0.57, 0.87) | 0.81 (0.55, 0.93) | 0.72 (0.59, 0.81) | **<0.001** |
| **HDLc (mg/dL)** | 7 (0.3%) | 56 (48, 66) | 54 (47, 62) | 59 (51, 69) | **<0.001** |
| **LDLc (mg/dL)** | 7 (0.3%) | 91 (77, 108) | 88 (73, 105) | 94 (80, 111) | **<0.001** |
| **Triacylglycerols (mg/dL)** | 10 (0.4%) | 65 (50, 89) | 64 (47, 86) | 67 (52, 92) | **<0.001** |
| **CRP (mg/dL)** | 34 (1.3%) | 0.09 (0.06, 0.40) | 0.10 (0.06, 0.40) | 0.09 (0.06, 0.36) | 0.2 |
| **CC-IMT (mm)** | 132 (4.9%) | 0.40 (0.36, 0.44) | 0.41 (0.37, 0.45) | 0.39 (0.35, 0.43) | **<0.001** |
| **Iron (μM)** | 2,371 (88%) | 12 (9, 16) | 13 (9, 17) | 12 (9, 16) | 0.4 |
| **Ferritin (ng/mL)** | 21 (0.8%) | 38 (24, 59) | 47 (30, 73) | 32 (19, 50) | **<0.001** |
| **Transferrin (g/L)** | 1,885 (70%) | 273 (251, 298) | 277 (253, 303) | 270 (249, 294) | **0.041** |
| **TSAT (%)** | 2,394 (89%) | 20 (15, 26) | 20 (15, 26) | 20 (15, 26) | 0.8 |

[1]Median (Q1, Q3); n (%)

[2]Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test[c]

**Table 4: Multivariable regression analysis of ferritin and CC-IMT**

| Parameter | Estimate | 95% CI | | Standard Error | Fraction of Missing Information (FMI) | Relative Increase in Variance (RIV) | p-value |
|---|---|---|---|---|---|---|---|
| | | Low | High | | | | |
| **Intercept** | 0.617 | 0.464 | 0.77 | 0.078 | 0.485 | 0.779 | **<0.0001** |
| **Ferritin (ng/mL)** | | | | | | | |
| **<66.4** | 0.025 | -0.113 | 0.163 | 0.07 | 0.548 | 0.983 | 0.726 |
| **66.4-130.5** | 0.1303 | 0.0192 | 0.241 | 0.057 | 0.591 | 1.156 | **0.0376** |
| **130.6-232.9** | 0.141 | -0.168 | 0.45 | 0.158 | 0.559 | 1.023 | 0.386 |
| **>233** | 0.082 | -0.102 | 0.265 | 0.094 | 0.174 | 0.195 | 0.383 |
| **Sex:F (ref=M)** | -0.002 | -0.175 | 0.171 | 0.089 | 0.103 | 0.11 | 0.982 |
| **Ferritin (ng/mL): Females** | | | | | | | |
| **<66.4** | -0.025 | -0.195 | 0.146 | 0.087 | 0.094 | 0.0995 | 0.774 |
| **66.4-130.5** | -0.078 | -0.243 | 0.087 | 0.084 | 0.343 | 0.453 | 0.358 |
| **130.6-232.9** | 0.251 | -0.153 | 0.655 | 0.206 | 0.127 | 0.139 | 0.224 |
| **>233** | 0.54 | 0.107 | 0.974 | 0.221 | 0.07 | 0.073 | **0.0148** |
| **Other covariates** | | | | | | | |
| **Age** | 0.139 | 0.132 | 0.146 | 0.003 | 0.046 | 0.047 | **<0.0001** |
| **Diabetes (ref= No Diabetes)** | 0.025 | 0.014 | 0.036 | 0.006 | 0.436 | 0.65 | **0.0001** |
| **Creatinine** | -0.006 | -0.016 | 0.003 | 0.005 | 0.764 | 2.458 | 0.215 |
| **HDLc** | -0.006 | -0.01 | -0.002 | 0.002 | 0.268 | 0.326 | **0.0035** |
| **LDLc** | 0.008 | 0.0043 | 0.012 | 0.0020 | 0.3757 | 0.516 | **0.0003** |
| **Triacylglycerols** | -0.003 | -0.006 | 0.008 | 0.002 | 0.077 | 0.08 | 0.1324 |
| **BMI** | 0.004 | -0.0002 | 0.008 | 0.002 | 0.044 | 0.045 | 0.066 |
| **Former smokers (ref=Nonsmokers)** | 0.017 | 0.008 | 0.025 | 0.0042 | 0.047 | 0.048 | **0.0001** |
| **Active smokers (ref=Nonsmokers)** | 0.019 | 0.0102 | 0.029 | 0.0047 | 0.243 | 0.288 | **0.0001** |
| **CRP** | 0.01 | 0.004 | 0.017 | 0.004 | 0.84 | 3.78 | **0.024** |
| **Hb** | 0.0098 | 0.004 | 0.016 | 0.0032 | 0.66 | 1.51 | **0.0103** |
| **SBP** | 0.018 | 0.013 | 0.023 | 0.0035 | 0.213 | 0.247 | **<0.0001** |
| **DBP** | -0.009 | -0.014 | -0.004 | 0.0035 | 0.195 | 0.23 | **0.0006** |

| Table 5: Multivariable regression analysis of transferrin and CC-IMT | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Parameter** | **Estimate** | **95% CI** | | **Standard Error** | **Fraction of Missing Information (FMI)** | **Relative Increase in Variance (RIV)** | **p-value** |
| | | **Low** | **High** | | | | |
| **Intercept** | 0.691 | 0.557 | 0.824 | 0.068 | 0.586 | 1.133 | **<0.0001** |
| **Transferrin (g/L)** | | | | | | | |
| **< 199** | -0.052 | -0.176 | 0.073 | 0.064 | 0.755 | 2.35 | 0.44 |
| **199-230** | -0.0116 | -0.0834 | 0.06 | 0.037 | 0.507 | 0.85 | 0.76 |
| **231-263** | -0.1428 | -0.4088 | 0.12 | 0.136 | 0.701 | 1.818 | 0.318 |
| **>263** | -0.181 | -0.379 | 0.007 | 0.098 | 0.259 | 0.313 | 0.063 |
| **Sex:F (ref=M)** | 0.489 | 0.057 | 0.921 | 0.22 | 0.74 | 2.14 | 0.055 |
| **Transferrin (g/L): Females** | | | | | | | |
| **< 199** | -0.4991 | -0.9282 | -0.0700 | 0.2189 | 0.7429 | 2.2095 | 0.0504 |
| **199-230** | -0.3030 | -0.5645 | -0.0415 | 0.1334 | 0.7488 | 2.2752 | 0.0517 |
| **231-263** | -0.9900 | -1.8072 | -0.1728 | 0.4169 | 0.6903 | 1.7307 | **0.0391** |
| **>263** | -0.1173 | -0.4455 | 0.2108 | 0.1674 | 0.4959 | 0.8109 | 0.4916 |
| **Other covariates** | | | | | | | |
| **Age** | 0.139 | 0.132 | 0.146 | 0.0034 | 0.039 | 0.04 | **<0.0001** |
| **Diabetes (ref= No Diabetes)** | 0.025 | 0.015 | 0.036 | 0.006 | 0.419 | 0.609 | **0.0001** |
| **Creatinine** | -0.006 | -0.015 | 0.003 | 0.005 | 0.758 | 2.39 | 0.227 |
| **HDLc** | -0.006 | -0.01 | -0.002 | 0.002 | 0.254 | 0.305 | **0.005** |
| **LDLc** | 0.009 | 0.005 | 0.013 | 0.002 | 0.346 | 0.458 | **0.0001** |
| **Triacylglycerols** | -0.002 | -0.005 | 0.002 | 0.002 | 0.09 | 0.093 | 0.3 |
| **BMI** | 0.004 | -0.0001 | 0.008 | 0.002 | 0.113 | 0.12 | 0.058 |
| **Former smokers (ref=Nonsmokers)** | 0.017 | 0.008 | 0.025 | 0.004 | 0.069 | 0.072 | **0.0001** |
| **Active smokers (ref=Nonsmokers)** | 0.019 | 0.01 | 0.029 | 0.005 | 0.23 | 0.28 | **0.0001** |
| **CRP** | 0.012 | 0.006 | 0.018 | 0.003 | 0.804 | 3.09 | **0.008** |
| **Hb** | 0.01 | 0.004 | 0.017 | 0.003 | 0.69 | 1.74 | **0.0128** |
| **SBP** | 0.018 | 0.013 | 0.023 | 0.003 | 0.22 | 0.26 | **<0.0001** |
| **DBP** | -0.009 | -0.013 | -0.004 | 0.002 | 0.153 | 0.17 | **0.0006** |

# Are there sex-specific associations between iron status and carotid intima-media thickness?



Individual participant data (IPD) from 21 published studies

**Pooled IPD Data (N=10,807)**

**UK Biobank (N=43,211)**

*Hemochromatosis genotypes*

- *C282Y (-/-) H63D (+/-)*
- *C282Y (-/-) H63D (+/+)*
- *C282Y (+/-) H63D (+/-)*
- *C282Y (+/-) H63D (-/-)*
- *C282Y (+/+) H63D (-/-)*

*CC-IMT Measurements*

- *Ultrasound*



Machine learning



Metaanalysis



Regression analysis

## Figure 2a. Flow of literature in the IPD




## Figure 2b. Machine learning pipeline




A. VIP plot
Age
CRP
Creatinine
LDLc
Transferrin
Hb
HDLc
Ferritin
Iron
BMI
Triacylglycerols
SBP
DBP
TSAT
Former_Smokers
Females
Diabetes
Active_Smokers
Hypertension
0.0
0.1
0.2
0.3
0.4
Importance
B. SHAPley plot
Age 0.0752
CRP 0.0180
LDLc 0.0129
HDLc 0.0102
SBP 0.0100
Transferrin 0.0092
Creatinine 0.0091
Females 0.0087
Ferritin 0.0073
Hb 0.0071
BMI 0.0062
Triacylglycerols 0.0040
TSAT 0.0032
Active_Smokers 0.0032
DBP 0.0030
Iron 0.0028
Hypertension 0.0025
Former_Smokers 0.0018
Diabetes 0.0016
-0.3
-0.2
-0.1
0.0
0.1
0.2
SHAP value
Feature value
High
Low